Titan Pharmaceuticals (TTNP)
(Delayed Data from NSDQ)
$5.70 USD
+0.16 (2.90%)
Updated Jul 29, 2024 03:30 PM ET
NA Value
NA Growth NA Momentum NA VGMBrokerage Reports
Titan Pharmaceuticals, Inc. [TTNP]
Reports for Purchase
Showing records 21 - 40 ( 113 total )
Company: Titan Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Titan Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Opiant Collaboration Offers Market Expansion Possibilities
Provider: Roth Capital Partners, Inc.
Analyst: HENRY S
Company: Titan Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Titan Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Titan Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Titan Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Titan Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Titan Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Titan Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Titan Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
4Q16 Recap - Probuphine Ramp Should Accelerate in 2H17
Provider: Roth Capital Partners, Inc.
Analyst: HENRY S
Company: Titan Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Titan Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Titan Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Titan Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
3Q16 Recap - Strong Potential, but Sales Cycle Will Take Time
Provider: Roth Capital Partners, Inc.
Analyst: HENRY S
Company: Titan Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Titan Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Titan Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
2Q16 Recap - Early Provider Certifications a Positive Leading Indicator
Provider: Roth Capital Partners, Inc.
Analyst: HENRY S
Company: Titan Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Titan Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.